zalifrelimab
zalifrelimab: sourced relationships with 1 company · 3 clinical trials tracked.
zalifrelimab evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could zalifrelimab → URGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| UroGen Pharma Ltd. (URGN) Non-muscle Invasive Bladder Cancer | Phase 3 |
Clinical Trial Registry Records (3)
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC
Primary endpoint: Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Primary endpoint: Objective Response Rate
A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
Primary endpoint: Phase 2: Objective Response Rate (ORR) - Independent Endpoint Review Committee (IERC)
Frequently asked questions
Which companies have sourced relationships with zalifrelimab?
zalifrelimab has dated SEC/FDA relationship records for UroGen Pharma Ltd..
How many clinical trials involve zalifrelimab?
BioSniper tracks 3 clinical trials involving zalifrelimab.